Peptide Knowledge Base · Hormonal

Triptorelin: what it is, what the evidence says, and its real status

A real approved drug (Trelstar) for serious oncology/endocrine indications, being misused in biohacker 'restart' protocols off-label.

Can you actually get it?

Plain-English verdict: No availability record.

Regulatory status: No regulatory record.

How does Triptorelin work?

A long-acting GnRH agonist that, after an initial flare, suppresses the reproductive hormone axis, the basis of its approved oncology/endocrine use.

What it does — and what it does not do

What it does: Approved and effective for its specific oncology and endocrine indications.

What it does not do: It is not a safe or proven 'hormone restart,' and that off-label biohacker use is inappropriate and not something we offer.

How honest is the evidence?

Evidence grade A — Strong human evidence.

grade A for approved indications; off-label 'restart' use unsupported

A grade measures how much human evidence exists, not whether a molecule is good, safe, or worth your interest. Read our grading methodology for what each grade means.

What we still don't know: The off-label 'restart' protocol has no controlled evidence and a real risk profile.

WADA status: Banned (S2).

Who should not take it

WADA S2 banned; off-label endocrine misuse carries significant risk; specialist-managed for approved use only.

Sources

Triptorelin (Trelstar) FDA labeling · GnRH-agonist endocrine literature

Compounded medications are not FDA-approved. We keep two signals separate and never collapse them: whether you can get something, and what the rule currently says. See the live FDA Peptide Tracker for status.

Join the founding list →

Embed this card on your site · free, CC BY 4.0, no key.

Last reviewed Jun 18, 2026 · Peptós.LIFE · Not medical advice.